Yellow fever vaccine. V. Antibody response in maonkeys inoculated with graded doses of the 17D vaccine.
A dosage equal to or greater than approximately 3.4 Dex (decimal exponent, log(10)) weanling mouse intracerebral 50% lethal dose (LD(50)) was sufficient to elicit a yellow fever antibody response, as determined by the plaque neutralization (PN) test, in better than 90% of vaccinated rhesus monkeys. Lower dosages were progressively less effective in terms of PN titers and the PN and hemagglutination-inhibition serological conversion rates observed. A dose of between 3.4 and 4.2 Dex weanling mouse intracerebral LD(50), or one-tenth to one times the dosage recommended for man, provided an optimal antibody response in monkeys. In rhesus monkeys, in contrast to the findings for man, pre-existing yellow fever antibody did not interfere with the antibody response to yellow fever vaccine. The PN test was felt to be a more sensitive and specific indicator of yellow fever antibody in rhesus monkeys after vaccination than the hemagglutination inhibition or complement fixation tests.
D000818:Animals; D000917:Antibody Formation; D000956:Antigens, Viral; D001103:Arboviruses / Q000276:immunology; D002460:Cell Line / Q000382:microbiology; D003168:Complement Fixation Tests; D000882:Haplorhini; D006385:Hemagglutination Inhibition Tests; D007273:Injections, Intramuscular; D007668:Kidney; D007928:Lethal Dose 50; D008251:Macaca; D051379:Mice; D009500:Neutralization Tests; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage*; D014776:Virus Cultivation; D015005:Yellow fever virus / Q000276:immunology*
D000956:Antigens, Viral; D014765:Viral Vaccines